OBiO Closes on ￥100M Series B+ Funding Round

According to PEdaily.cn, OBiO Technology (Shanghai) Co., Ltd. ("OBiO") has completed its series B + financing of over 100 million yuan, with participation from GP Capital, Sinowisdom and Efung Capital. Since the establishment in March 2013, OBiO has obtained three rounds of financing with the total amount reaching hundreds of millions of yuan.

OBiO is a domestic leading high-tech enterprise, which focuses on viral vector packaging service for both basic life science research and gene & cell therapy drug development and clinical preparation in China. The company was listed on "National Equities Exchange and Quotations" (NEEQ Market, ID:839702, stock name: Heyuan Shanghai) on December 16th, 2016.

Located at Shanghai International Medical Zone (SIMZ), OBiO offers adeno-associated virus (AAV), lentivirus, adenovirus and retrovirus packaging services for experimental, preclinical and clinical research mainly in neuroscience, oncology, metabolism, cardiovascular disease. OBiO has an integrative base over 6,000 square meters of research and development, pilot production, and business office. The services of OBiO have extended from viral packaging to gene editing (CRISPR/Cas9 etc.), exosome detecting, long non-coding RNA analysis and other advanced biotech services.

In addition, OBiO provides overall solutions of gene therapy research CRO services for domestic universities, scientific research institutions, medical institutions, and pharmaceutical companies. For process development, OBiO starts comprehensive strategic cooperation in gene therapy with General Electric Healthcare ("GE Healthcare") in 2016. For drug research and development, OBiO has several pipelines, including tumor target AAV drug, antibody and antibody-drug conjugate against tumors, viral constructs for CAR-T therapy. The gene therapy drug AAV-TRAIL has already entered the stage of clinical application.

GP Capital, the manager of Shanghai Financial Development Investment Fund, was established in July 2009 with a registered capital of 120 million yuan.  The company is mainly engaged in the establishment, operations management, and investment operations of industrial investment funds and private equity funds of other types. 

Founded in 2002, Sinowisdom is a Chinese domestic private investment venture capital management agency. There are more than 60 funds under the management of Sinowisdom, with the capital of more than 10 billion yuan and over 170 investment projects. The company focuses on investment in the field of Internet, artificial intelligence, health care, high-end equipment, big data, new materials.